AbbVie ABBV Business Segments
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Net revenues by Product | ||||||
| All other | $1.03B-18.2% | $617M-18.0% | $660M-9.1% | $603M-25.6% | $1.25B+68.4% | |
| Botox Cosmetic | $668M+20.1% | $717M+4.4% | $637M-5.1% | $692M-5.1% | $556M-12.2% | |
| Botox Therapeutic | $1.01B+16.5% | $990M+13.4% | $985M+16.2% | $928M+14.0% | $866M+15.8% | |
| Elahere | $198M+10.6% | $182M+23.0% | $170M+22.3% | $159M+24.2% | $179M+180% | |
| Epkinly | $83M+62.7% | $81M+102% | $69M+60.5% | $70M+94.4% | $51M+88.9% | |
| Humira | $688M-38.6% | $1.25B-25.9% | $993M-55.4% | $1.18B-58.1% | $1.12B-50.6% | |
| Imbruvica | $556M-24.7% | $671M-20.9% | $706M-14.7% | $754M-9.5% | $738M-11.9% | |
| Juvederm Collection | $232M+0.4% | $249M-10.8% | $253M-1.9% | $260M-24.2% | $231M-22.2% | |
| Linzess | $283M+91.2% | $175M-24.9% | $326M+39.3% | $258M+16.7% | $148M-44.4% | |
| Mavyret | $351M+14.7% | $324M+11.3% | $312M+3.3% | $375M+1.6% | $306M-12.3% | |
| Other Aesthetics | $286M-9.2% | $320M-3.6% | $303M-2.3% | $327M+2.8% | $315M-1.3% | |
| Other Neuroscience | $125M-19.4% | $47M-16.1% | $46M-17.9% | $55M-11.3% | $155M+138% | |
| Qulipta | $296M+53.4% | $288M+43.3% | $288M+63.6% | $267M+78.0% | $193M+47.3% | |
| Rinvoq | $2.12B+23.3% | $2.37B+29.4% | $2.18B+35.3% | $2.03B+41.8% | $1.72B+57.2% | |
| Skyrizi | $4.48B+30.9% | $5.01B+32.5% | $4.71B+46.9% | $4.42B+62.2% | $3.43B+70.6% | |
| Ubrelvy | $339M+41.3% | $339M+11.9% | $354M+31.6% | $338M+46.3% | $240M+18.2% | |
| Venclexta | $770M+15.8% | $710M+8.4% | $726M+7.2% | $691M+8.5% | $665M+8.3% | |
| Vraylar | $905M+18.3% | $1.02B+10.6% | $934M+6.7% | $900M+16.3% | $765M+10.2% | |
| Vyalev | $201M+219% | $183M+316% | $138M+393% | $98M+444% | $63M+600% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does AbbVie break its business down?
- AbbVie (ABBV) reports net revenues by product across 19 parts — All other, Botox Cosmetic, Botox Therapeutic, Elahere and Epkinly. Each is extracted from the segment footnotes and tracked over time.
- Where does AbbVie's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in AbbVie's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
